San Diego-dependent Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug market place in February right after revealing promising data from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when given as being a weekly injection and in March